Clinical trials: copd or chronic obstructive
COPD
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD
This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for…
- Trial name
- GOLDEN-3 (NCT02347761)
- Testing
- SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer
- Where
- 44 sites in United States
- Volunteers
- 653 people
- Sponsor
- Sunovion Respiratory Development Inc.
COPD
Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI
This study proposes to use hyperpolarized xenon-129 Magnetic Resonance Imaging (MRI) to study lung function of COPD patients who will receive endobronchial valve (EBV) therapy as part of their clinical standard-of-care.
- Trial name
- NCT05433961
- Testing
- MagniXene Hyperpolarized Xenon MRI
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Xemed LLC
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
This study aims at evaluating efficacy and safety of Symbicort® Turbuhaler® in Chinese COPD patients as defined by GOLD treatment guidelines in order to obtain an approval for indication of COPD from Chinese State Food and Drug…
- Trial name
- NCT00421122
- Testing
- budesonide/formoterol (Symbicort), budesonide (Pulmicort), terbutaline sulfate (Bricasol)
- Where
- 8 sites in China
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
This study will assess the pharmacokinetics (PK), pharmacodynamics (PD) and safety of ensifentrine and glycopyrrolate fixed dose (FDC) product, the individual components of the FDC (ensifentrine and glycopyrrolate, each in the…
- Trial name
- NCT07132983
- Testing
- Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects
This study will investigate the safety and pharmacokinetics (PK) of a single dose of GSK2256294 in healthy young and elderly subjects to explore the effects of food, gender and age on drug exposure.
- Trial name
- NCT02006537
- Testing
- GSK2256294
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma, Respiratory Candidiasis
The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
This study tests the effects of an experimental drug PC945 in people with asthma or other chronic respiratory diseases whose lungs are infected by Aspergillus fungi and Candida yeasts.
- Conditions
- Asthma, Respiratory Candidiasis, Respiratory Aspergillosis, COPD
- Trial name
- NCT03745196
- Testing
- PC945
- Where
- 4 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pulmocide Ltd
Renal Anemia, Chronic
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
This study will compare the efficacy and safety of subcutaneous Mircera and subcutaneous darbepoetin in the treatment of renal anemia in participants with chronic kidney disease who are not on dialysis and not receiving…
- Trial name
- NCT00559273
- Testing
- Methoxy polyethylene glycol-epoetin beta, Darbepoetin alfa
- Where
- 76 sites in Australia, Belgium and 14 more
- Volunteers
- 307 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease
Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD
A prospective observational multi centre research study in GP practices clustered within up to 10 UK Primary care trusts.
- Trial name
- INHALE (NCT02123199)
- Testing
- Indacaterol (Onbrez®) /QAB149
- Where
- United Kingdom
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT01908140
- Testing
- Aclidinium Bromide / Formoterol Fumarate, Salmeterol / Fluticasone
- Where
- 126 sites in Austria, Bulgaria and 12 more
- Volunteers
- 933 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and…
- Trial name
- FAST (NCT01922271)
- Testing
- NVA237, Tiotropium, Salbutamol
- Where
- 14 sites in Germany
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics
This is a first time in human (FTIH) study designed to evaluate the safety, tolerability and pharmacokinetic (PK) profile of single and repeat doses of GSK3923868 inhalation powder in both healthy participants and asthmatics.
- Trial name
- NCT04585009
- Testing
- GSK3923868, Monodose RS01
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
GSK2190915A - Bioavailability Study
GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that reduces inflammation in cells. This study will evaluate three capsule and two tablet formulations to select the optimal formulation for further…
- Trial name
- NCT02224521
- Testing
- GSK2190915 Solution., GSK2190915 Granule Capsule (A), GSK2190915 Semi-solid Lipid Capsule (B)
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD, Chronic Diseases
A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment
The purpose of this study is to ensure the quality of the COPD treatment in primary care by implementing planned follow-up visits, where the disease condition is evaluated and optimised in accordance with the national COPD…
- Trial name
- KOSMOS (NCT00772733)
- Where
- 11 sites in Denmark
- Volunteers
- 936 people
- Sponsor
- AstraZeneca
COPD
A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD
The purpose of this study is to investigate the efficacy, safety and tolerability of AD 237 in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00242333
- Testing
- AD 237
- Where
- 33 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 300 people
- Sponsor
- Sosei
Chronic Obstructive Pulmonary Disease (COPD)
Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population
The purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single doses of inhaled LAS100977 in COPD patients.
- Trial name
- NCT01425814
- Testing
- LAS100977, Reference
- Where
- 8 sites in Germany
- Volunteers
- 87 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease
A study to evaluate the effects of ACT-541468 on respiration in patients with moderate chronic obstructive pulmonary disease
- Trial name
- NCT03646864
- Testing
- ACT-541468
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Disease, Chronic Obstructive, COPD
Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)
The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with COPD.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00396604
- Testing
- indacaterol maleate
- Where
- Belgium
- Volunteers
- 51 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)
The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with chronic obstructive pulmonary disease (COPD) who completed the 24-week evaluation of study…
- Trial name
- NCT00246935
- Testing
- Roflumilast
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)
This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) and MF/F…
- Trial name
- NCT00383435
- Testing
- Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI
- Volunteers
- 1,055 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.
This study will involve the use of a new compound, GW642444 that is being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00519376
- Testing
- GW642444M, GW642444H
- Where
- 4 sites in Germany
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.